Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

LIGAND PHARMACEUTICALS INC Director's Dealing 2021

Feb 5, 2021

31289_dirs_2021-02-05_4aafa87f-72b0-43c4-a2b7-4eeef0d6fb9f.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: LIGAND PHARMACEUTICALS INC (LGND)
CIK: 0000886163
Period of Report: 2021-02-03

Reporting Person: FOEHR MATTHEW W (President and COO)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-02-03 Common Stock A 6595 $0.0 Acquired 167198 Direct
2021-02-04 Common Stock M 1000 $74.42 Acquired 168198 Direct
2021-02-04 Common Stock M 44547 $21.92 Acquired 212745 Direct
2021-02-04 Common Stock S 44547 $176.86 Disposed 168198 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-02-04 Employee Stock Option (right to buy) $21.92 M 44547 Disposed 2023-02-15 Common Stock (44547) Direct
2021-02-04 Employee Stock Option (right to buy) $74.42 M 1000 Disposed 2024-02-12 Common Stock (1000) Direct
2021-02-03 Employee Stock Option (right to buy) $177.5 A 13136 Acquired 2031-02-03 Common Stock (13136) Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $169.52 to $180.89, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F2: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/15/13.

F3: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/12/14.

F4: Grant to reporting person of options to purchase shares of common stock ("Option Shares"), exerciseable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 02/03/2021.